DeepMed Research

NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

Assessing Optimal XR-Buprenorphine Initiation Points in Jail

Phase 4

Withdrawn

Conditions: Opioid Use Disorder

Interventions: Drug: Extended-Release Buprenorphine Injection

First Posted Date: 2022-08-01

Last Posted Date: 2024-02-29

Lead Sponsor: NYU Langone Health

Registration Number: NCT05481112

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Enteral Feeding and Splanchnic NIRS Values in Infants With Neonatal Encephalopathy (NE)

Not Applicable

Completed

Conditions: Neonatal Encephalopathy

Interventions: Procedure: Enteral Feeding

First Posted Date: 2022-07-22

Last Posted Date: 2024-05-02

Lead Sponsor: NYU Langone Health

Target Recruit Count: 40

Registration Number: NCT05471336

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

RELAXaHEAD for Headache Patients (Phase II)

Not Applicable

Completed

Conditions: Migraine
Multiple Sclerosis
Headache
Insomnia

Interventions: Behavioral: Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)
Behavioral: Monitored Usual Care (MUC)

First Posted Date: 2022-07-20

Last Posted Date: 2024-01-10

Lead Sponsor: NYU Langone Health

Target Recruit Count: 48

Registration Number: NCT05466682

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Community-engaged Hypertension Prevention Program in Black Men

Not Applicable

Active, not recruiting

Conditions: Hypertension

Interventions: Behavioral: Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)
Behavioral: Barbershop-Based Facilitation (BF)

First Posted Date: 2022-07-07

Last Posted Date: 2025-04-18

Lead Sponsor: NYU Langone Health

Target Recruit Count: 430

Registration Number: NCT05447962

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2

Recruiting

Conditions: Melanoma
Unresectable Melanoma

Interventions: Drug: Sarilumab
Drug: Ipilimumab Injection
Drug: Nivolumab/Relatlimab

First Posted Date: 2022-06-22

Last Posted Date: 2025-02-04

Lead Sponsor: NYU Langone Health

Target Recruit Count: 69

Registration Number: NCT05428007

Locations: 🇺🇸
The Angeles Clinic at Cedars Sinai, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Life Study: Lifestyle Intervention in Fibroid Elimination

Not Applicable

Active, not recruiting

Conditions: Uterine Fibroid

Interventions: Other: LIFE program

First Posted Date: 2022-06-13

Last Posted Date: 2025-02-26

Lead Sponsor: NYU Langone Health

Target Recruit Count: 100

Registration Number: NCT05416424

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Presence or Absence of Blood in the GI Lumen

Not Applicable

Completed

Conditions: Upper GI Bleeding

Interventions: Device: HemoPill

First Posted Date: 2022-06-10

Last Posted Date: 2025-01-20

Lead Sponsor: NYU Langone Health

Target Recruit Count: 15

Registration Number: NCT05415124

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Psilocybin Therapy in Advanced Cancer

Phase 2

Recruiting

Conditions: Advanced Cancer

Interventions: Drug: Niacin 100mg
Drug: Psilocybin 25 mgs
Behavioral: Psychotherapy

First Posted Date: 2022-06-01

Last Posted Date: 2025-01-15

Lead Sponsor: NYU Langone Health

Target Recruit Count: 300

Registration Number: NCT05398484

Locations: 🇺🇸
University of Colorado Anschutz Medical campus (CU AMC), Aurora, Colorado, United States
🇺🇸
NYU Langone Health, New York, New York, United States

Making Resident Well-Being a (Virtual) Reality

Not Applicable

Withdrawn

Conditions: Mental Health

Interventions: Other: Guided Mediation Virtual Reality App

First Posted Date: 2022-05-27

Last Posted Date: 2024-01-10

Lead Sponsor: NYU Langone Health

Registration Number: NCT05395221

Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder

Phase 4

Recruiting

Conditions: Post Traumatic Stress Disorder

Interventions: Drug: Saline
Drug: Bupivacaine

First Posted Date: 2022-05-26

Last Posted Date: 2025-02-25

Lead Sponsor: NYU Langone Health

Target Recruit Count: 90

Registration Number: NCT05391971

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy